Publications by authors named "R D Mercer"
Background: Ontario has publicly funded biosimilar bevacizumab for first-line metastatic colorectal cancer (mCRC) since 2019. Clinical trials demonstrate comparable efficacy and safety of bevacizumab biosimilars to originator bevacizumab. The objective of this study was to assess real-world safety and effectiveness of the implementation of bevacizumab biosimilars compared with originator bevacizumab in patients with mCRC.
View Article and Find Full Text PDFObjective: Clinical practice guideline recommendations are often informed by systematic reviews. This review aimed to appraise the reporting and methodological quality of systematic reviews informing clinical practice recommendations relevant to vascular surgery.
Data Sources: MEDLINE and Embase.
Article Synopsis
- - The study analyzed body composition changes in NBA athletes throughout different seasonal phases (preseason, pre all-star, post all-star, and offseason) using DXA scans from 62 players over 11 years, focusing on factors like age and player height.
- - Results indicated that players generally increase lean mass (LM) and decrease fat mass (FM) during the in-season phases, with older athletes showing a greater gain in LM, while height was positively correlated with both LM and FM increases.
- - The research introduced a custom region of interest (ROI) technique for accurate assessments of taller athletes and highlighted the need for personalized body composition evaluations, which can inform strategies for strength, nutrition, and player development in professional basketball. *
Genetic prion diseases are caused by mutations in PRNP, which encodes the prion protein (PrP). Why these mutations are pathogenic, and how they alter the properties of PrP are poorly understood. We have consented and accessed 22 individuals of a multi-generational Israeli family harboring the highly penetrant E200K PRNP mutation and generated a library of induced pluripotent stem cells (iPSCs) representing nine carriers and four non-carriers.
View Article and Find Full Text PDFObjectives: MVASI (Amgen) and Zirabev (Pfizer) are 2 of the earliest bevacizumab biosimilars approved for the first-line treatment of metastatic colorectal cancer (mCRC). We aimed to confirm and quantify the real-world cost savings and cost-effectiveness of MVASI and Zirabev relative to originator bevacizumab for patients with mCRC.
Methods: We conducted a population-based, retrospective cohort study in Ontario, Canada, where originator and biosimilar bevacizumab are universally publicly funded.